CERTIFICATION OF ENROLLMENT

SUBSTITUTE SENATE BILL 5838



59th Legislature
2006 Regular Session

Passed by the Senate February 10, 2006
  YEAS 34   NAYS 4


________________________________________    
President of the Senate
Passed by the House February 28, 2006
  YEAS 96   NAYS 1


________________________________________    
Speaker of the House of Representatives


CERTIFICATE

I, Thomas Hoemann, Secretary of the Senate of the State of Washington, do hereby certify that the attached is SUBSTITUTE SENATE BILL 5838 as passed by the Senate and the House of Representatives on the dates hereon set forth.


________________________________________    
Secretary
Approved 









________________________________________    
Governor of the State of Washington
FILED







Secretary of State
State of Washington


_____________________________________________ 

SUBSTITUTE SENATE BILL 5838
_____________________________________________

Passed Legislature - 2006 Regular Session
State of Washington59th Legislature2005 Regular Session

By Senate Committee on Health & Long-Term Care (originally sponsored by Senators Kastama, Benson, Poulsen, Brandland, Deccio, Keiser, Thibaudeau, Franklin and Rasmussen)

READ FIRST TIME 03/02/05.   



     AN ACT Relating to the substitution of a preferred drug for a nonpreferred drug in hepatitis C virus treatments; and amending RCW 69.41.190.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

Sec. 1   RCW 69.41.190 and 2003 1st sp.s. c 29 s 5 are each amended to read as follows:
     (1) Any pharmacist filling a prescription under a state purchased health care program as defined in RCW 41.05.011(2) shall substitute, where identified, a preferred drug for any nonpreferred drug in a given therapeutic class, unless the endorsing practitioner has indicated on the prescription that the nonpreferred drug must be dispensed as written, or the prescription is for a refill of an antipsychotic, antidepressant, chemotherapy, antiretroviral, or immunosuppressive drug, or for the refill of a immunomodulator/antiviral treatment for hepatitis C for which an established, fixed duration of therapy is prescribed for at least twenty-four weeks but no more than forty-eight weeks, in which case the pharmacist shall dispense the prescribed nonpreferred drug.
     (2) When a substitution is made under subsection (1) of this section, the dispensing pharmacist shall notify the prescribing practitioner of the specific drug and dose dispensed.

--- END ---